These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38279527)

  • 21. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.
    Pencina MJ; D'Agostino RB; Zdrojewski T; Williams K; Thanassoulis G; Furberg CD; Peterson ED; Vasan RS; Sniderman AD
    Eur J Prev Cardiol; 2015 Oct; 22(10):1321-7. PubMed ID: 25633587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method.
    Whelton SP; Meeusen JW; Donato LJ; Jaffe AS; Saenger A; Sokoll LJ; Blumenthal RS; Jones SR; Martin SS
    J Clin Lipidol; 2017; 11(4):1065-1072. PubMed ID: 28826567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis.
    Vaverkova H; Karasek D; Novotny D; Jackuliakova D; Lukes J; Halenka M; Frohlich J
    Clin Biochem; 2009 Aug; 42(12):1246-51. PubMed ID: 19450572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study.
    Benn M; Nordestgaard BG; Jensen GB; Tybjaerg-Hansen A
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):661-70. PubMed ID: 17170368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.
    Sniderman AD; Dufresne L; Pencina KM; Bilgic S; Thanassoulis G; Pencina MJ
    Eur Heart J; 2024 Jul; 45(27):2410-2418. PubMed ID: 38700053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
    Idris I; Tate H; Ahmad A; McCormack T
    J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels.
    Jun JE; Choi YJ; Lee YH; Kim DJ; Park SW; Huh BW; Lee EJ; Jee SH; Hur KY; Choi SH; Huh KB
    Korean J Intern Med; 2018 Jan; 33(1):138-147. PubMed ID: 29334727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concordance/discordance between serum apolipoprotein B, low density lipoprotein cholesterol and non-high density lipoprotein cholesterol in NATPOL 2011 participants - An epidemiological perspective.
    Solnica B; Sniderman AD; Wyszomirski A; Rutkowski M; Chlebus K; Bandosz P; Pencina MJ; Zdrojewski T
    Int J Cardiol; 2023 Nov; 390():131150. PubMed ID: 37429441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice.
    De Oliveira-Gomes D; Joshi PH; Peterson ED; Rohatgi A; Khera A; Navar AM
    Circulation; 2024 Jul; 150(1):62-79. PubMed ID: 38950110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study.
    Mora S; Buring JE; Ridker PM; Cui Y
    Ann Intern Med; 2011 Dec; 155(11):742-50. PubMed ID: 22147713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
    van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
    Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein B Displays Superior Predictive Value Than Other Lipids for Long-Term Prognosis in Coronary Atherosclerosis Patients and Particular Subpopulations: A Retrospective Study.
    Zhang C; Ni J; Chen Z
    Clin Ther; 2022 Aug; 44(8):1071-1092. PubMed ID: 35902283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).
    Cao J; Nomura SO; Steffen BT; Guan W; Remaley AT; Karger AB; Ouyang P; Michos ED; Tsai MY
    J Clin Lipidol; 2020; 14(1):109-121.e5. PubMed ID: 31882375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of high-sensitivity C-reactive protein levels in functional outcomes in patients with large-artery atherosclerosis and small-artery occlusion.
    Hou D; Liu J; Feng R; Gao Y; Wang Y; Wu J
    Neurol Res; 2017 Nov; 39(11):981-987. PubMed ID: 28749740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
    Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
    Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.
    Rehman MB; Tudrej BV
    Lipids Health Dis; 2024 Sep; 23(1):316. PubMed ID: 39334349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.
    Robinson JG; Wang S; Jacobson TA
    Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.